Idera Pharmaceuticals, Inc. (IDRA) Reports Fourth Quarter And Year End 2013 Financial Results And Provides Corporate Update
3/13/2014 6:54:22 AM
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today reported its financial and operational results for the fourth quarter and year ended December 31, 2013.
Help employers find you! Check out all the jobs and post your
comments powered by